Drug intelligence / Profile preview

OT-601

Development stage: Unknown
Lead developer: Ocumension Biotech
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

OT-601 is a 0.5% moxifloxacin hydrochloride ophthalmic solution developed by Ocumension Therapeutics. As a fourth-generation fluoroquinolone antibiotic, it exerts its antibacterial effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential enzymes for bacterial DNA replication, transcription, repair, and recombination. This topical formulation is approved in China for the treatment of bacterial conjunctivitis. Additionally, it is utilized as a component of combination products, such as OT-601-C, which are under development for the management of postoperative inflammation following ocular surgery.

Other names: moxifloxacin hydrochloride ophthalmic solutionmoxifloxacin hydrochloride eye drops

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on OT-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT-601.

Explore the full profile